Drug Profile
Ad26 Mos4 HIV tetravalent vaccine - Janssen Vaccines and Prevention B.V
Alternative Names: Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos4.HIV; Adenovirus serotype-26 mosaic-4 HIV vaccine; Adenovirus serotype-26 mosaic-4 human immunodeficiency virus vaccine; Tetravalent Ad26 Mos HIV; VAC 89220Latest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Crucell Holland
- Developer Beth Israel Deaconess Medical Center; Janssen Vaccines and Prevention B.V
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III HIV infections
- Phase I/II Immunodeficiency disorders; Immunological disorders; Retrovirus infections; Sexually transmitted infections
Most Recent Events
- 12 Jan 2024 US Army Medical Research and Development Command and Janssen Vaccines and Prevention plans a phase I trial for HIV infection (Prevention) in January 2024 in Uganda (IM) (NCT06205056)
- 10 Aug 2023 Janssen Vaccines & Prevention B.V. completes a phase III trial in HIV infections (Prevention) in Poland, Puerto Rico, Peru, Mexico, Italy, Brazil, Argentina, Spain, USA (IM) (NCT03964415) (EudraCT2018-003666-13)
- 18 Jan 2023 Efficacy and adverse events data from a phase III MOSAICO trial in HIV infections (Prevention) released by Janssen Vaccines and Prevention B.V